
Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target
Arcutis Biotherapeutics (ARQT) Analyst Ratings
Bulls say
Arcutis Biotherapeutics is attractive fundamentally because ZORYVE has become a differentiated branded topical franchise across plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, with foam and cream formulations matching distinct patient-use cases and a potent PDE4 mechanism that supports best-in-class efficacy and tolerability. Commercial execution is strong, as reported Zoryve sales rose from $29M in 2023 to $167M in 2024 and $372M in 2025, while 2Q26 Zoryve sales reached $129.9M, up 59% year over year, contributing to raised 2026 net product sales guidance of $525M to $540M and positive net income of $15.0M in 2Q26. The outlook is further strengthened by limited direct branded competition in seborrheic dermatitis, expanding access and sales infrastructure, and multiple upside catalysts from vitiligo, hidradenitis suppurativa, and ARQ-234 that are not yet reflected in the model.
Bears say
Arcutis Biotherapeutics is viewed negatively because its growth case hinges on multiple approvals and a timely 2/23/27 PDUFA that are not guaranteed, while Zoryve still needs approval in scalp psoriasis. The company also faces intense commercialization risk from generic topical products and Vtama, with uptake dependent on physician demand, payor access, and prior authorization, while higher gross-to-net discounts could pressure the 2026E Zoryve guide of $525–$540M. On top of that, reliance on Interquim for supply, rising operating expenses, and the need for additional capital create meaningful execution and financing risk.
This aggregate rating is based on analysts' research of Arcutis Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcutis Biotherapeutics (ARQT) Analyst Forecast & Price Prediction
Start investing in Arcutis Biotherapeutics (ARQT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Arcutis Biotherapeutics (ARQT) Forecast
Arcutis Biotherapeutics (ARQT) Analyst Forecast & Price Prediction
Start investing in Arcutis Biotherapeutics (ARQT)
Order type
Buy in
Order amount
Est. shares
0 shares